BioVie's announcement regarding a phase 2 trial for its lead therapy helped raise the stock's price.
The company is forging ahead with a phase 3 trial for its lead therapy.
The biotech announced positive news from a pair of phase 2 clinical trials.
Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.
The average of price targets set by Wall Street analysts indicates a potential upside of 52.1% in BioVie Inc. (BIVI). While the effectiveness of this highly sought-after metric is questionable, the positive...
If you are looking for stocks that are well positioned to maintain their recent uptrend, BioVie Inc. (BIVI) could be a great choice. It is one of the several stocks that passed through our "Recent Price...
The more investors learned about BioVie's latest clinical results, the more they liked.
The clinical-stage biotech released data on its prospective Alzheimer's therapy.
December S&P 500 futures (ESZ22) are trending up +0.08% this morning after three major US benchmark indices finished the regular session sharply lower as market participants fretted that stronger-than-anticipated...
Here is how BioVie Inc. (BIVI) and Immunovant, Inc. (IMVT) have performed compared to their sector so far this year.